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Abstract
Objective—While it is accepted that macrophage glycolysis is up-regulated under hypoxic 
conditions, it is not known whether this is linked to a similar increase in macrophage pro-
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inflammatory activation and whether specific energy demands regulate cell viability in the 
atheromatous plaque.
Approach and Results—We studied the interplay between macrophage energy metabolism, 
polarization and viability in the context of atherosclerosis. Cultured human and murine 
macrophages and an in vivo murine model of atherosclerosis were used to evaluate the 
mechanisms underlying metabolic and inflammatory activity of macrophages in the different 
atherosclerotic conditions analyzed. We observed that macrophage energetics and inflammatory 
activation are closely and linearly related, resulting in dynamic calibration of glycolysis to keep 
pace with inflammatory activity. Additionally, we show that macrophage glycolysis and 
proinflammatory activation mainly depend on hypoxia-inducible factor (HIF) and on its impact on 
glucose uptake, and on the expression of hexokinase II and ubiquitous 6-phosphofructo-2-kinase 
(PFKFB3). As a consequence, hypoxia potentiates inflammation and glycolysis mainly via these 
pathways. Moreover, when macrophages’ ability to increase glycolysis through PFKFB3 is 
experimentally attenuated, cell viability is reduced if subjected to proinflammatory and/or hypoxic 
conditions, but unaffected under control conditions. In addition to this, GM-CSF enhances 
anaerobic glycolysis while exerting a mild pro-inflammatory activation.
Conclusions—These findings, in human and murine cells and in an animal model, show that 
hypoxia potentiates macrophage glycolytic flux in concert with a proportional up-regulation of 
pro-inflammatory activity, in a manner that is dependent on both HIF-1α and PFKFB3.
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Introduction
A body of research extending over three-quarters of a century shows that myeloid cells 
including macrophages are highly dependent on glycolysis for energy metabolism 1. 
Subsequently, several lines of evidence have linked macrophage pro-inflammatory 
activation with cellular energetics 2–4. However, the precise nature of this link remains 
poorly understood. It was recently shown that hypoxic macrophages up-regulate the 
expression of glucose transporters, hexokinase II and the ubiquitous form of 6-
phosphofructo-2-kinase (encoded by PFKFB3) in order to substantially increase the 
glycolytic flux 5. However, it remains unknown if this increased glycolytic flux occurs in 
order to simply maintain constant energy delivery in an anaerobic environment or it parallels 
a similar increase in pro-inflammatory activation. Moreover, the relationship between 
macrophage pro-inflammatory activation and energetics is not well understood in the setting 
of an atherogenic milieu. Accordingly, in this series of investigations, we sought to 
investigate the relationship between two fundamental processes: energy metabolism and 
inflammatory activation of macrophages in an atherogenic environment.
Inflammation plays an important role in a wide range of diseases. Atherosclerosis is a 
chronic inflammatory condition accounting for the largest share of mortality in the 
developed world 6 and is one of the most devastating of inflammatory conditions. 
Consequently, there is a critical need for greater understanding of the biological mechanisms 
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underlying atherosclerotic inflammation and its complications, including plaque rupture and 
intraplaque hemorrhage 7, 8. Atherosclerosis is characterized by macrophage-predominated 
inflammation existing in the context of pro-inflammatory cytokines, oxidized low-density 
lipoproteins (oxLDL), and hypoxia within the arterial wall 9–12. Despite mounting evidence 
that hypoxia promotes inflammation in cancer, obesity and other inflammatory diseases13, in 
atherosclerosis, the mechanism and precise contribution of hypoxia to other plaque 
constituents (e.g. cytokines [CK] and oxLDL) on the pro-inflammatory milieu remains to be 
established and a recent study questioned whether pro-inflammatory stimuli present in 
atheroma up-regulate macrophage glucose metabolism at all 14.
We studied macrophage responses to a range of pro-inflammatory stimuli relevant to 
atherosclerosis, and observed that pro-inflammatory stimuli substantially increased both the 
rate of glycolysis (flux) and pro-inflammatory activation (e.g. TNF-α production). 
Moreover, we found that glycolytic flux and pro-inflammatory activation show a significant 
correlation over a range of physiological inflammatory stimuli and across normoxic and 
hypoxic conditions. We also noted that hypoxia substantially potentiates the effect of 
cytokines on both glycolytic flux and pro-inflammatory activation (in similar proportions). 
We then demonstrated that blocking hypoxia sensing or enzymes responsible for high 
glycolytic flux substantially reduced both the pro-inflammatory activation and the glycolytic 
flux of macrophages. Moreover, inhibition of glycolysis after PFKFB3 expression has a 
profound effect on murine and human macrophage viability, leading to enhanced necrotic 
and apoptotic death under pro-inflammatory conditions. Subsequently, we confirmed the in 
vivo relevance of our findings in an animal model.
Materails and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Hypoxia Potentiates Macrophage Pro-Inflammatory Activation and Glycolysis
In atherosclerosis, as with other inflamed tissues, the microenvironment plays a key role in 
determining the activation state of macrophages. Cytokines are an important constituent of 
the inflammatory milieu influencing macrophage commitment along a classical (M1 pro-
inflammatory) or alternative (M2 anti-inflammatory) polarization 15. To establish a firm 
basis for the series of experiments in this study, we sought to confirm the known effects of 
various M1 vs. M2 activators on elicited peritoneal murine macrophage polarization. 
Additionally, we evaluated the relative action of GM-CSF (GM), a cytokine that is relevant 
to the atheroma and a potent macrophage regulator 16, which served as a physiological 
classical stimulus given its ubiquitous, endogenous expression in rodents and humans 16–22. 
Despite the relative importance of GM-CSF to macrophage biology in vivo, the metabolic 
impact of GM-CSF on macrophage metabolism is not well understood. Accordingly, we 
examined macrophages after exposure to CK (classical stimuli: TNF-α, IL-1β, IFN-γ), LPS 
(innate stimulus), IL4/IL13 (alternative stimulus) as well as GM-CSF. Using complementary 
techniques to evaluate the polarization (Fig. 1A–D), we observed as expected that M1 
markers increased after classic or innate activation (with LPS and CK), while M2 markers 
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increased after stimulation with IL4/IL13. We furthermore observed that GM-CSF exerts a 
M1-like polarization, resulting in mild increases in NO and TNF-α accumulation, (Fig. 
1B,C), well-accepted signatures of the M1 activation 23–25. Further, under either classic or 
innate stimuli, we observed a shift in the gene expression of the bifunctional enzyme 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB), from the liver type-PFK2 
(PFKFB1), which has a low net kinase activity, to the more active inducible form PFKFB3 
(Fig. 1D). This response was further exacerbated under hypoxic conditions, as suggested by 
the increased HIF-1α levels (Fig. 1E,F). It is well established that PFKFB3 has greater 
kinase than bisphosphatase activity 26 and thus favors the rise in fructose-2,6-bisphosphate 
(Fru-2,6-P2), a potent regulator of upper glycolysis that is required for high glycolytic 
rates 5, 26, 27.
Observations under Atherogenic Conditions
Next, we evaluated the actions of key atherosclerotic constituents (oxLDL, LDL, and 
hypoxia) 7, 28 on murine macrophage pro-inflammatory activation and glycolysis. We found 
that oxLDL and GM-CSF (but not LDL) each resulted in pro-inflammatory activation of 
murine macrophages (Fig. 2A). Notably, hypoxia on its own did not increase pro-
inflammatory stimulation. However, in cells exposed to GM-CSF and/or oxLDL, hypoxia 
substantially potentiated pro-inflammatory activation (Fig. 2A, right). The effects on 
glycolysis of these atherosclerotic constituents were similar to those on TNF-α production: 
oxLDL, GM-CSF, and CK each resulted in substantial increases in Fru-2,6-P2 concentration 
(Fig. 2B). Moreover, while hypoxia alone caused a minimal increase in glycolysis, hypoxia 
markedly potentiated the glycolytic flux in the presence of proatherogenic mediators 
(cytokines and oxLDL) (Fig. 2B, right; Fig. 2C). Furthermore, while hypoxia alone was not 
associated with an increase in glucose consumption in non-activated macrophages, hypoxia 
substantially potentiated the effect of CK and GM-CSF (Fig. 2D). These results agree with 
the expression levels of genes encoding the glucose transporter Glut-1 as well as the genes 
encoding HK-II and PFKFB3, the enzyme responsible for the high-throughput synthesis of 
Fru-2,6-P2. We observed a similar action of hypoxia on the expression of those genes: 
hypoxia had a minor impact on its own, but substantially potentiated the actions of CK and 
GM-CSF (Fig. 2E).
Close Interrelationship between Glycolysis and Pro-Inflammatory Activation. Role of TNF-
α
Because we observed that both macrophage pro-inflammatory activation and energetics 
increase in the presence of atherosclerotic mediators, we sought to define the strength of the 
interrelationship between these two processes. We observed a strong linear correlation 
(R=0.97; P<0.001) between glycolytic flux (as Fru-2,6-P2 levels) and pro-inflammatory 
activity (measured as TNF-α production) under both hypoxic and normoxic conditions Fig. 
3A. Hence, we demonstrate that macrophage glycolysis keeps pace with the pro-
inflammatory activated state of the cell regardless of oxygen tension. Moreover, since GM-
CSF promotes TNF-α synthesis, we sought to determine its contribution to the glycolytic 
phenotype. As Fig. 3B shows, the presence of neutralizing antibodies against TNF-α in the 
culture medium significantly attenuated the expression of PFKFB3, the rise in Fru-2,6-P2 
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levels and the release of lactate, providing a link for TNF-α between the inflammatory and 
glycolytic profiles.
PFKFB3 Regulates both Glycolytic Metabolism and Inflammation
Given the strong linear association between macrophage glycolysis and inflammatory 
activity in murine cells, we next sought to evaluate whether: 1) a high glycolytic rate was 
necessary for inflammatory activation, and 2) this relationship was maintained in human 
macrophages. To investigate this human macrophages were separately treated with two 
inhibitors of PFKFB3: i) a human small interfering RNA (siRNA) targeting PFKFB3, and ii) 
3PO, a selective inhibitor of PFKFB3 29. In the first experiment, we observed that silencing 
PFKFB3 effectively attenuated PFKFB3 without impacting the constitutively expressed 
PFKFB1 or HK-II (Fig. 4A), and thus did not affect basal glycolysis (Fig. 4B). However, we 
observed that inhibition of PFKFB3 activity under stimulatory conditions results in a 
significant reduction in glycolytic flux (measured as Fru-2,6-P2 levels and lactate release; 
Fig. 4B and Fig. S1A–B, respectively). In parallel to these findings, we found that blocking 
PFKFB3 resulted in a significant reduction in pro-inflammatory activation (measured by 
TNF-α production; Fig. 4C) across oxygen tensions and under a range of stimuli.
Thereafter, we tested the hypothesis that high-flux glycolysis is required to maintain 
macrophage viability under conditions of pro-inflammatory stimulation. In this experiment, 
we observed that blocking PFKFB3 did not reduce the viability of resting macrophages; 
however, under conditions of pro-inflammatory stimulation, the viability of activated 
macrophages decreased when PFKFB3 was inhibited (Fig. 4D). Taken together, these 
observations provide evidence that the ability to up-regulate PFKFB3 activity is necessary to 
maintain the viability of activated (but not resting) macrophages.
HIF-1α also Regulates both Glycolytic Metabolism and Inflammation
Since we observed that hypoxia potentiates macrophage pro-inflammatory activation, we 
hypothesized that interruption of hypoxia-sensing might attenuate inflammation in an 
atherosclerotic environment. Indeed, within the context of cancer, it has recently been shown 
that hypoxia-induced over-expression of HIF-1α results in metabolic adaptation (a shift to 
glycolysis from Krebs cycle and oxidative phosphorylation) which in turn facilitates cell 
survival 30. We sought to evaluate whether a similar relationship exists in atherosclerotic 
macrophages. We observed that silencing HIF-1α substantially reduced glycolytic flux (as 
Fru-2,6-P2 levels and lactate; Fig. 5A,B) across oxygen tensions and under various pro-
inflammatory conditions. In parallel, blocking HIF-1α substantially reduced pro-
inflammatory activation of macrophages (as TNF-α production; Fig. 5C). Further, we 
observed that inhibition of either PFKFB3 and/or HIF-1α, resulted in proportionate 
reductions in both glycolysis (as Fru-2,6-P2) and pro-inflammatory activation (R=0.68, 
P=0.007; Fig. 5D). In addition to this, we evaluated the role of hypoxia on the inducibility of 
PFKFB3 in response to GM-CSF. As Fig. 5E shows, macrophages transfected with a 
plasmid carrying the HRE sequence of the human pfkfb3 promoter (29 nucleotides, from 
−1297 to −1269) linked to a luciferase reporter 31–33 exhibited an increase in activity due to 
hypoxia, but also by the action of GM-CSF, a response that was enhanced under hypoxic 
conditions. Collectively, these observations suggest that both up-regulation of upper 
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glycolysis and pro-inflammatory activation are dependent on HIF-1α across oxygen 
tensions, highlighting the crosstalk between hypoxic and non-hypoxic signaling pathways in 
the regulation of metabolic adaptation in response to atherosclerotic stimuli. Indeed, 
silencing of HIF-1α provoked a loss in viability with increased rates of apoptosis and 
necrosis compared to controls (Fig. 5F). This was especially evident in the presence of 
oxLDL or under hypoxic conditions. This finding reaffirms that an intact HIF-1α system is 
required for macrophage survival in an atherosclerotic microenvironment and that survival 
of activated macrophages is also dependent on high glycolytic flux, through up-regulation of 
PFKFB3. In addition to this, O2 consumption decreased in M1 macrophages. Moreover, 
under low glucose availability, forcing respiration with FCCP resulted in cell death of M1 
cells, but not in resting or M2 counterparts (Fig. 6A). Moreover, GM-CSF depressed 
mitochondrial ATP synthesis (Fig. 6B), but enhanced non-mitochondrial O2 consumption in 
agreement with ROS production, in particular in the presence of oxLDL (Fig. 6C,D).
Inhibition of PFKFB3 and HIF-1α Attenuates Glycolytic Flux in ApoE−/− Mice
We then sought to evaluate the impact of selective inhibition of PFKFB3 and HIF-1α on 
glycolytic flux in atherosclerotic mice (ApoE−/− mice fed a high-fat diet). Glycolysis in the 
arterial wall was assessed using FDG PET/CT imaging before and after impairing PFKFB3 
(using 3PO or PFKFB3 siRNA) and HIF-1α (using HIF-1α siRNA). Subsequently, we 
removed the arterial segments and measured tissue levels of PFKFB3, Fru-2,6-P2, TNF-α 
and CCL2. We observed substantial attenuation of glycolysis (measured as a target-to-
background ratio of FDG uptake; TBR) after inhibition of either PFKFB3 and/or HIF-1 α 
(Fig. 7A). Moreover, after removal of the arterial tissues, we measured the tissue quantities 
of PFKFB3 and Fru-2,6-P2, and found that their tissue levels mirrored the measurements of 
FDG uptake across the tested conditions (Fig. 7B,C). Similarly, the tissue measurements of 
pro-inflammatory mediators TNF-α and CCL2 were similarly affected by the inhibitors 
(Fig. 7D). Also, silencing or inhibition of PFKFB3 resulted in an enhancement of active 
caspase 3 in the plaque (Fig. 7E) confirming the loss in cell viability under these conditions. 
Interestingly, all animals were alive and stable after treatment courses. Given the tenacious 
relationship between glycolysis and inflammation, these in vivo observations raise the 
possibility that antagonism of HIF-1α and/or modulation of glycolysis may provide a 
pharmacologic approach to alleviate the inflammatory burden in atherosclerotic disease.
Discussion
The findings of this study highlight the basis for and importance of macrophage metabolic 
adaptation within atherosclerosis. We show that hypoxia potentiates macrophage glycolytic 
flux along with a proportional up-regulation of pro-inflammatory activity (in a manner that 
is dependent on both HIF-1α and PFKFB3). Moreover, we show that antagonizing either 
HIF-1α or PFKFB3 activities simultaneously impairs both glycolysis and pro-inflammatory 
activation in vitro, and we provide translational evidence of this phenomenon in vivo. 
Further, we show that impairing either HIF-1α or PFKFB3 in the setting of pro-
inflammatory stimulation results in loss of monocyte viability after activation of caspase 
cascades. The potential impact of reduced monocyte/macrophage viability in atherosclerotic 
plaques is unclear. Macrophage proliferation within plaque has been described 34, and 
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reduced viability of such cells, as well perhaps of other macrophages may indeed be 
beneficial. However, there is also the possibility of detrimental effects of enhancing cell 
death with possible post-apoptotic necrosis if efferocytosis is deficient. Thus, further work is 
needed to better understand the implications of such modulation of macrophage viability 
within the atheroma.
The observation that hypoxia increases glycolysis is a phenomenon referred to, in cancer 
cells, as the Warburg Effect 35, and appears to be involved in macrophage physiology at 
different points of their maturation and function 36. One proposed explanation for Warburg’s 
observation is that hypoxia obligates a shift in metabolism, from the tricarboxylic acid cycle 
to glycolysis simply to compensate for loss of aerobic metabolism 37. However, our 
observations provide an alternate explanation for the Warburg Effect, at least as far as it 
relates to atherosclerotic macrophages, namely that 1) hypoxia also increases the pro-
inflammatory activation of macrophages and, that 2) the glycolytic rate is increased in a 
manner that keeps pace with this increased inflammatory and proatherogenic activity, 
namely due to the contribution of oxLDL to the enhanced glucose consumption and ROS 
production 10, 11. Collectively, these observations give rise to a paradigm wherein hypoxia 
can act to exacerbate a cycle of inflammation (Fig. 8). Within this paradigm, cytokines 
trigger up-regulation of HIF-1α, which is stabilized under hypoxic conditions 38, 39. HIF-1α, 
after transcriptional induction of PFKFB3 leads to increased pro-inflammatory activation as 
well as increased glycolysis 5, 29, 32, 33, 40, 41. The activated macrophages then produce 
additional cytokines to perpetuate this vicious inflammatory cycle.
Our data have potentially important implications for the treatment of atherosclerotic 
inflammation. We found that selective inhibition (or silencing) of PFKFB3, HIF-1α, or both 
results in a substantial reduction in pro-inflammatory activation. Along these lines, PFKFB3 
has been recently shown to play a regulatory role in proliferation 34, 41 and angiogenesis 40. 
Accordingly, drugs that target PFKFB3 or hypoxia sensing, which are also currently in 
development as cancer therapeutics 42–45, should be further studied in the context of 
atherosclerosis. Moreover, studies should assess whether targeting PFKFB3 or reducing 
hypoxia sensing within plaques will decrease atherosclerotic inflammation and its clinical 
consequences. Indeed, in a previous work using macrophages deficient for HIF-1α in the 
myeloid lineage 5 we were surprised by the observation that glycolysis remained increased 
and PFKFB3 was also overexpressed, perhaps due to the fact that HIF-2α assumed part of 
the transcriptional control due to HIF-1α 46. Therefore, the rationale for the use of PFKFB3 
inhibitors offers many advantages since this enzyme is only expressed under hypoxic and 
pro-inflammatory conditions.
The study’s findings also have important implications for imaging of atherosclerosis. While 
the bulk of prior evidence suggests that pro-inflammatory stimulation is associated with 
increased glycolysis, one recent study suggested that hypoxia and not pro-inflammatory 
activation augments macrophage glucose metabolism 14. That report proposed that imaging 
measures of glucose metabolism (e.g. with labeled 2-deoxyglucose), may provide an 
indirectly assessment tissue hypoxia in vivo 14. However, the findings of the current study 
suggest that measures of glycolysis are not well suited for assessing hypoxia. Specifically, 
we observe, across oxygen tensions, that glycolytic flux remains tightly related to the state 
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of macrophage pro-inflammatory activity, (e.g. TNF-α production, see Fig. 3), thus 
supporting the use of FDG to image inflammatory cell activity within atheromatous plaques. 
On the other hand, we found that oxygen tension per se is not a good predictor of the degree 
of inflammation, since pro-inflammatory activity varies quite markedly within both 
normoxic and hypoxic conditions, depending on the availability of other pro-inflammatory 
factors such as oxidized LDL and cytokines (see Fig. 2A). Accordingly, hypoxia-directed 
probes (such as FMISO), while likely co-localize to sites of inflammation, may not be so 
useful for reporting on the level of pro-inflammatory activation that exists in those lesions.
The central importance of inflammation to atherosclerosis, warrants pursuit of a deeper 
understanding of the interconnection between hypoxia, glycolysis and inflammatory 
activation within an atheroma. This study demonstrates that a surprisingly tight inter-
connection exists between macrophage glycolysis and pro-inflammatory activity, that the 
link requires HIF-1α and transcriptional induction of PFKFB3, and that inhibition of either 
under pro-inflammatory conditions results in a reduction in inflammatory activity. Hence, 
modulation of macrophage metabolic adaptation may provide an opportunity to develop 
novel treatments against atherosclerotic inflammation.
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SIGNIFICANCE
The present data show a connection between macrophage viability, activation and oxygen 
availability that impacts macrophage function in an atherosclerotic environment. This 
tight inter-connection between macrophage glycolysis and pro-inflammatory activity, 
requiring HIF-1α and transcriptional induction of PFKFB3, is susceptible to be 
modulated by pharmacological inhibitors of PFKFB3 (and HIF-1α). Therefore, selective 
inhibition of glycolytic activity may result in a loss of macrophage function and a 
potential stabilization of atherosclerotic lesions, with relevance in the pharmacologic 
management of atherogenesis.
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Fig. 1. Characterization of the interplay between macrophage polarization and glycolytic 
enzymes
Peritoneal murine macrophages were incubated with GM-CSF (20 ng/ml), LPS (200 ng/ml), 
CK (TNF-α, IL-1β and IFN-γ; 20 ng/ml each) or IL4+IL13 (20 ng/ml). Cells were 
maintained under normoxic or hypoxic conditions (1% O2) for 18h prior to challenge. (A) 
left, Western blot of phospho-STAT-5 and phospho-ERK to ensure a selective GM-CSF 
response; right, expression of M1 and M2 polarization markers in response to the indicated 
stimuli. (B) The time-course of the accumulation of nitrate plus nitrite in the culture medium 
was measured. (C) The accumulation of TNF-α was measured as an index of macrophage 
activation at 8h. (D) mRNA levels of M1 (TNF-α, IL-6, PFKFB3) and M2 (Arg-1, IL-10) 
polarization markers. (E–F) Western blot analysis of HK-II, PFKFB3, PFKFB1 and HIF-1α 
under normoxic and hypoxic conditions (left). Relative band intensity ratios levels of HK-II, 
PFKFB3 and PFKFB1 were determined (F). Results show a representative blot out of three 
(A,E). Results show the mean±SD of four experiments (B,C,F).*P<0.05; **P<0.01 vs. non 
stimulated cells.
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Fig. 2. Hypoxia potentiates murine macrophage pro-inflammatory activation and glycolytic flux
Murine macrophages were incubated with GM-CSF (20 ng/ml), CK (TNF-α, IL-1β and 
IFN-γ; 20 ng/ml each) or treated with LDL or oxLDL (50 μg/ml). Cells were maintained 
under normoxic (20% O2) or hypoxic (1% O2) conditions for 18h prior to challenge. (A) 
TNF-α measurement (8h) served as an index of macrophage activation (note, TNF-α was 
not assessed after CK, since CK contains TNF-α; N.D.= not determined). (B) Intracellular 
levels of Fru-2,6-P2 were measured at the end of the experiment (24h). (C) Lactate 
accumulation in the culture medium (24h), and (D) glucose consumption from 8 to 24h 
across oxygen tensions after cytokine challenge. (E) Time-course of indicated mRNA levels 
under normoxia (top) and hypoxia (bottom) after cytokine treatment. Results show the mean
±SD of four experiments. #P<0.05; ##P<0.01 vs. the same O2 in the absence of LDL or 
oxLDL (A,B); *P<0.05; **P<0.01 vs. the same condition under normoxia (A–C), vs. the 
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same condition in the absence of cytokine (D), vs. the same condition at 0h (E). N.D=not 
etermined
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Fig. 3. Close interrelationship between murine macrophage pro-inflammatory activation (TNF-
α) and Fru-2,6-P2 concentration as indicator of glycolysis
(A) Correlation between the accumulation of TNF-α in the culture medium and intracellular 
Fru-2,6-P2 concentrations under the experimental conditions described in Figs. 1–2. (B) 
Neutralizing goat anti-mouse TNF-α Abs (10 μg/ml) in the culture medium prevent 
PFKFB3 induction, the rise in Fru-2,6-P2 concentration and the release of lactate in 
macrophages treated for 24h with GM-CSF (20 ng/ml) under normoxic and hypoxic (1% 
O2) conditions. Goat IgG (10 μg/ml) was used as control immunoglobulin. Results show a 
representative blot and the mean±SD of three experiments. **P<0.01 vs. the same IgG 
condition.
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Fig. 4. Inhibition of PFKFB3 attenuates energy metabolism, pro-inflammatory activation and 
viability in activated human macrophages
Human macrophages were maintained under normoxia or hypoxia, and transfected for 18h 
with a specific pool of siRNA (5 nM) to silence PFKFB3, or inactive RNA control (scRNA) 
and then activated with human GM-CSF and CK (used at 20 ng/ml each). (A) PFKFB3, 
PFKFB1, HK-II and β-actin were assessed by Western blot. (B,C) Glycolytic flux (as 
Fru-2,6-P2 concentration) and pro-inflammatory activation (as TNF-α accumulation) were 
determined after PFKFB3 silencing with siRNA or inhibition with 3PO (10 μM). (D) 
Cellular viability was assessed in the absence/presence of PFKFB3 inhibition (by 3PO). 
Results show a representative blot out of three (A) or the mean±SD of 3–4 experiments (B–
D). *P<0.05; **P<0.01 vs. the same condition with fully active PFKFB3; #P<0.05; ##P<0.01 
vs. the same condition under normoxia (B,C). N.D.= not determined.
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Fig. 5. Silencing HIF-1α decreases human macrophage energetics, pro-inflammatory activation 
and viability
Human macrophages were maintained under normoxia or hypoxia and silenced with siRNA 
for HIF-1α (5 nM). (A,B) Effect of siRNA for HIF-1α on the levels of Fru-2,6-P2 and 
lactate release after stimulation with GM-CSF or CK (20 ng/ml each). (C) Time course of 
TNF-α accumulation under hypoxia and after silencing HIF-1α. (D) Interrelationship 
between TNF-α and Fru-2,6-P2 levels under the different experimental conditions described 
in Fig. 4 and 5 (including normoxia, hypoxia, LDL and oxLDL and silencing PFKFB3 and 
HIF-1α), and inhibition of PFKFB3 (3PO; 10 μM). (E) After transfection of macrophages 
with a luciferase reporter plasmid containing the HRE domain of the pfkfb3 promoter, or the 
mutated sequence lacking HRE binding (pHREwt.Luc and pHREmut.Luc, respectively at 
600 ng/ml each) and a β-galactosidase plasmid (60 ng/ml) cells were submitted for 4h to 
normoxia or hypoxia (1% O2) and then activated for 6h with GM-CSF. The ratio between 
the luciferase and β-galactosidase activities was determined for in the same cell extracts. (F) 
After activation for 60h with GM-CSF or CK, the percentage of apoptotic/necrotic cells was 
determined. Results show the mean±SD (n=3) (A,B,D) or a representative experiment out of 
three (C). *P<0.05; **P<0.01 vs. the same condition with scRNA (A,B), vs. the basal 
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condition under normoxia (E) or vs. the corresponding LDL condition 
(F). #P<0.05; ##P<0.01 vs. the same condition under normoxia (A,B).
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Fig. 6. Real time changes in the oxygen consumption rate (OCR) and ROS production in human 
macrophages under atherogenic conditions
Cells were maintained for 18h with complete medium or medium with 1 mM glucose and 
activated with CK (20 ng/ml), GM-CSF (20 ng/ml), LDL and oxLDL (50 μg/ml) or 
combinations of these. (A) The OCR was measured and then cells were treated with 
oligomycin (inhibitor of ATP synthase), FCCP (ionophore to ‘force’ O2 consumption) and 
rotenone+antimycin A (inhibitors of the electron-transport chain). (B) Basal O2 
consumption (area under the curve, AUC) as measured during the early 20 min in A. (C) 
Non-mitochondrial respiration, corresponding to cells treated with antimycin A plus 
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rotenone. (D) ROS production by macrophages measured by the oxidation of DCFH. 
Results show the mean (A) or the mean±SD (n=4) (B–D). *P<0.05; **P<0.01 vs. the same 
condition without GM-CSF; #P<0.05; ##P<0.01 vs. the none condition.
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Fig. 7. In vivo glycolytic flux measurement with 2GD and FDG-PET in atherosclerotic ApoE-
deficient mice
(A) TBR in male ApoE deficient mice fed a high fat diet for three weeks and silenced for 
HIF-1α, PFKFB3, or treated i.p. with the PFKFB3 inhibitor 3PO (50 mg/kg in Solutol) at 
days 3, 7, 10, 14 and 17 prior to FDG study. (B) Intra-plaque PFKFB3 levels were 
determined by Western blot and normalized for β-actin levels. (C) Intra-plaque Fru-2,6-P2 
concentration and (D) TNF-α and CCL2 levels. (E) Intra-plaque active caspase 3 protein 
levels (normalized with β-actin) and enzymatic activity, using N-acetyl-DEVD-7-amino-4-
trifluoromethylcoumarin as substrate. C+= positive control of macrophages treated for 24h 
with 0.5 mM GSNO. Results show the mean±SD (n=4–9 animals; 30 animals in total). 
*P<0.05; **P<0.01 vs. the absence of treatment (A,C,D) or expressed as percentage (B,E).
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Fig. 8. Hypoxia potentiates macrophage pro-inflammatory activation, thereby strengthening a 
vicious cycle
(A) Cytokines trigger up-regulation of HIF-1α, which is further stabilized by hypoxic 
conditions. HIF, after binding to the promoter region of PFKFB3 leads to increased 
glycolysis as well as to increased pro-inflammatory activation and maintained viability. The 
viable activated macrophages then produce additional cytokines to perpetuate this vicious 
inflammatory cycle. Antagonism of HIF-1α and/or PFKFB3 results in decreased pro-
inflammatory activation and metabolism as well as reduced viability.
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